Skyhawk Therapeutics
- Active openings
- 2
- US-based roles
- 0
- Remote-friendly
- 0
- Last updated
- 2026-09-16
What Skyhawk Therapeutics is hiring for
Open positions
2 activeAbout Skyhawk Therapeutics
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
Skyhawk Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Skyhawk reports positive first results in Huntington's patients for oral drug
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders